Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1/2 study of subretinal AAVB-039 for Stargardt disease
NL-OMON61048Phase 2Not yet recruiting
- Sponsor
- AAVantgarde Bio
- Start
- Dec 2025
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2 trial of AAVB-039, sponsored by AAVantgarde Bio. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
AAVB-039
Beyond the preview
Go deeper on NL-OMON61048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61048.